GGTI298 (Trifluoroacetate)

GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC50 of 3 μM; little effect on Ha-Ras with IC50 of >20 μM.

Product Specifications

CAS Number

[1217457-86-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/GGTI298_Trifluoroacetate.html

Purity

99.87

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)C[C@@H](C(OC)=O)NC(C1=CC=C(NC[C@@H](N)CS)C=C1C2=C3C=CC=CC3=CC=C2)=O.O=C(O)C(F)(F)F

Molecular Formula

C29H34F3N3O5S

Molecular Weight

593.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Sheikh IA, et al. The Epac1 signaling pathway regulates Cl- secretion via modulation of apical KCNN4c channels in diarrhea. J Biol Chem. 2013 Jul 12;288 (28) :20404-15.|[2]Chen S, et al. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Mol Cancer. 2010 Jan 29;9:23.|[3]McGuire TF, et al. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem. 1996 Nov 1;271 (44) :27402-7.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Arthritis Res Ther. 2024 Dec 19;26 (1) :222.|J Neuroinflammation. 2024 Nov 14;21 (1) :295.|J Oral Biosci. 2023 Dec;65 (4) :347-355.|Mol Cell Proteomics. 2023 Aug;22 (8) :100593.|Nat Commun. 2025 Nov 21;16 (1) :10263.|Int Immunopharmacol. 2023 Apr:117:110014.